Literature DB >> 18269366

Testing mechanisms of action for intensive case management.

Jon Morgenstern1, Kimberly A Blanchard, Christopher Kahler, Kirsten M Barbosa, Barbara S McCrady, Katharine H McVeigh.   

Abstract

AIM: This study identified factors that predict, mediate or moderate the effects of intensive case management (ICM) on longer-term drug abstinence outcomes in women on welfare.
DESIGN: In a parent study women were assigned randomly to usual care (UC) or intensive case management (ICM). Treatment was provided for 12 weeks and follow-up continued for 15 months after study intake. A set of hypothesized mediators was assessed at month 3 and a rigorous four-step mediational model was tested using outcomes in months 4-15. PARTICIPANTS: Participants were 302 drug-dependent women applying and eligible for federal welfare and not currently in drug abuse treatment. Interventions ICM provided intensive treatment engagement including voucher incentives for treatment attendance and case management services; UC provided primarily referral to community treatment programs. MEASUREMENT: Substance use outcomes were assessed using the time-line follow-back interview and confirmed using biological and collateral measures.
FINDINGS: Participants in ICM had more case manager contacts, better treatment engagement and more self-help attendance than did those in UC. Each of these variables predicted, and was shown to be a mediator of outcome, but case management contact was an especially robust mediator. Further, ICM effects were strongest for those who attended treatment least. Contrary to prediction, greater psychopathology and environmental stressors did not predict worse outcomes.
CONCLUSIONS: Findings suggest that case management is an active intervention that may both facilitate and substitute for formal drug abuse treatment.

Entities:  

Mesh:

Year:  2008        PMID: 18269366     DOI: 10.1111/j.1360-0443.2007.02100.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  6 in total

1.  Influence of site differences between urban and rural American and Central European opioid-dependent pregnant women and neonatal outcome characteristics.

Authors:  Andjela Baewert; Reinhold Jagsch; Bernadette Winklbaur; Gerda Kaiser; Kenneth Thau; Annemarie Unger; Constantin Aschauer; Manfred Weninger; Verena Metz
Journal:  Eur Addict Res       Date:  2012-02-21       Impact factor: 3.015

2.  Improving 24-month abstinence and employment outcomes for substance-dependent women receiving temporary assistance for needy families with intensive case management.

Authors:  Jon Morgenstern; Charles J Neighbors; Alexis Kuerbis; Annette Riordan; Kimberly A Blanchard; Katharine H McVeigh; Thomas J Morgan; Barbara McCrady
Journal:  Am J Public Health       Date:  2008-12-04       Impact factor: 9.308

3.  Psychiatric Symptom Improvement in Women Following Group Substance Abuse Treatment: Results from the Women's Recovery Group Study.

Authors:  R Kathryn McHugh; Shelly F Greenfield
Journal:  J Cogn Psychother       Date:  2010-04-01

4.  Depression's moderation of the effectiveness of intensive case management with substance-dependent women on temporary assistance for needy families: outpatient substance use disorder treatment utilization and outcomes.

Authors:  Alexis N Kuerbis; Charles J Neighbors; Jon Morgenstern
Journal:  J Stud Alcohol Drugs       Date:  2011-03       Impact factor: 2.582

5.  Underexamined points of vulnerability for black mothers in the child welfare system: The role of number of births, age of first use of substances and criminal justice involvement.

Authors:  Tricia Stephens; Alexis Kuerbis; Caterina Pisciotta; Jon Morgenstern
Journal:  Child Youth Serv Rev       Date:  2019-10-31

6.  A practical clinical trial of coordinated care management to treat substance use disorders among public assistance beneficiaries.

Authors:  Jon Morgenstern; Aaron Hogue; Sarah Dauber; Christopher Dasaro; James R McKay
Journal:  J Consult Clin Psychol       Date:  2009-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.